Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering...

Area of Science:

• Oncology
• Immunotherapy
• Cellular Engineering

Background:

• CD19-targeted chimeric antigen receptor (CAR) T cell therapies revolutionized B-cell malignancy treatment.
• Challenges include antigen escape, low CAR T-cell persistence, and manufacturing difficulties.
• Current viral vector-based CAR T-cell production is complex and costly.

Purpose of the Study:

• To develop a virus-free cell-engineering system for multiplex CAR T-cell therapies.
• To demonstrate the efficient production of functional CD20/CD19 dual-targeted CAR T-stem memory (CAR-TSCM) cells.
• To evaluate the in vitro and in vivo efficacy and safety of qPB™-manufactured CAR-TSCM cells.

Main Methods:

• Utilized the Quantum pBac™ (qPB™) piggyBac transposon-based vector for virus-free CAR T-cell engineering.
• Developed CD20/CD19 dual-targeted CAR-TSCM cells.
• Assessed cell expansion, tumor eradication in vitro and in vivo, and safety using an iCasp9 suicide gene system.

Main Results:

• Achieved efficient, consistent, and robust production of functional CAR-TSCM cells using the qPB™ system.
• Demonstrated rapid tumor eradication in vivo by qPB™-manufactured CAR-T cells.
• Confirmed safe control of CAR-T cells via an iCasp9 suicide gene-inducing drug.

Conclusions:

• The qPB™ system offers a simple, efficient method for manufacturing multiplex CAR-T cells.
• This virus-free approach has the potential to improve CAR T-cell therapy efficacy.
• The technology may broaden the accessibility of advanced CAR T-cell therapies for cancer patients.